By Joey Wong, Director of Investor Research, Hong Kong BD, LSN
At the upcoming RESI Boston conference this June, the panel Beyond Big Pharma: Partnering Early to Foster Innovation offers a rare window into how pharmaceutical companies identify, evaluate, and engage with early-stage innovators. As the healthcare industry continues to prioritize external innovation, pharma firms are increasingly scouting novel therapeutics at earlier stages than ever before. This panel brings together industry leaders who are on the front lines of these partnerships.
Panelists include:
 Marc Appel Managing Partner Pacific Bridge NY (Moderator) |
 Salma Al-Zu’bi Investment Principal Hikma Ventures |
 Dirk, Büscher Sr Director Grifols Innovation and New Technologies Grifols |
 Chloé Lepretre Head of Global R&D Search and Evaluation Servier |
 Nicolas Stalder Sr. Investment Manager Debiopharm Innovation Fund |
This panel will shed light on how pharma companies, whether the biggest players or mid-size companies, source assets, the evaluation process behind partnering decisions, and what factors drive interest at the earliest stages of development. Panelists will also share perspectives on the evolving therapeutics landscape, where unmet needs remain, and what kinds of assets are positioned to lead in the years ahead.
Whether you’re a first-time founder or a seasoned entrepreneur, this session will help demystify the strategic thinking behind pharma partnerships and provide tangible guidance for building investor interest.
RESI Boston is your gateway to strategic investors, global pharma leaders, and actionable feedback. Join us in person this June to attend this panel and over a dozen others, meet with investors through our partnering system, and experience the collision factor that defines RESI.
Next Phase Newsletter 